Section 32 is a fund with a focus on biotech and healthcare startups. The fund was established in 2017 by Bill Maris, the former founder and CEO of GV (fka Google Ventures).
Phone: 858-633-3232
2033 San Elijo Ave.
#565
San Diego, 92007
California, United States
| Date | Company | Round | Amount | Co-investors |
|---|---|---|---|---|
| 2018-09-05 | Fulcrum Therapeutics | Series B | $80M | 6 Dimensions Capital, Casdin Capital, Fidelity Investments, Foresite Capital, Leerink Partners, NS Investment, and Sanofi Ventures |
| 2018-07-25 | Alector | Series E | $133M | AbbVie Biotech Ventures, Amgen Ventures, Casdin Capital, Deerfield Management, Dementia Discovery Fund, Euclidean Capital, Federated Equity Funds - Federated Kaufmann Fund, Foresite Capital, Google Ventures, Lilly Asia Ventures, Mission Bay Capital, MRL Ventures, New Leaf Venture Partners, OrbiMed Advisors, Perceptive Advisors, and Polaris Partners |
| 2018-07-24 | MetroMile | Series E | $90M | Australian Future Fund, Index Ventures, Intact Financial Corporation, New Enterprise Associates, and Tokio Marine Holdings |
| 2018-07-17 | Dialpad | Series D | $50M | Amasia, Andreessen Horowitz, ICONIQ Capital, Scale Ventures, and Work-Bench |
| 2018-07-12 | Octave Bioscience | Series A | $14M | BlueCross BlueShield Venture Partners, and Echo Health Ventures |
